Trastuzumab biosimilar (Hualan Biological Engineering)
重组抗人表皮生长因子受体2（HER2）单抗（华兰基因工程）
Report date: 2026/05/26 20:00:28
Base Information
Drug NameTrastuzumab biosimilar (Hualan Biological Engineering)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC Code
Related LinksN/A